Forbes September 6, 2023
Rita Numerof

The pharmaceutical industry has long anticipated the dreaded day that finally arrived last week. The Department of Health and Human Services (HHS) released a list of the first 10 drugs selected for price negotiation by the Centers for Medicare & Medicaid Services (CMS). By invoking the “nuclear option,” Congress and the Biden Administration achieved through the Inflation Reduction Act (IRA) what they have long been after politically: to rein in the pharmaceutical industry as a means to try and reduce the high cost of prescription drugs and lower healthcare costs.

On finally “beating” big pharma, President Biden triumphantly said “well, we did it.”

We did not arrive at this ill-conceived legislative outcome overnight, and the government’s regulatory war against big...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, CMS, Congress / White House, Govt Agencies, HHS, Insurance, Medicare, Patient / Consumer, Pharma, Pharma / Biotech
Pharma Pulse 11/25/24: Deepening Patient Relationships, Menopause May Increase Risk of Asthma & more
Axolotl Biosciences Brings Biotech to the Forefront at Formnext 2024
Innovative approach maps gene activity in the living human brain
Trump tariffs could drive up generic drug costs: 5 takeaways
Bridging the Gap: Pharmacists' Role in Advancing Pharmacogenomic Testing Standards

Share This Article